

# Enhancing Tumor Targeting and Apoptosis Using Noncovalent Antibody Homodimers

\*Yunfeng Zhao and \*†Heinz Kohler

*\*Department of Microbiology and Immunology, University of Kentucky; and †Immpheron Incorporated, Lexington, Kentucky, U.S.A.*

---

**Summary:** A rare type of antibody that spontaneously binds to each self (homodimerizes) has been described. This self-binding (autophilic) antibody provides stronger protection against bacterial infection than a non self-binding antibody with identical specificity and affinity due to increase of polymeric avidity. A peptide derived from the self-binding domain of the autophilic antibody was crosslinked to the Fc carbohydrate of two monoclonal antibodies specific for the B-cell receptor (BCR) of a murine and a human B-cell tumor. Peptide-crosslinked antibodies bind to themselves on solid phase ELISA as homodimer and establish in solution a monomer-dimer equilibrium. Autophilic antibodies bind to their respective tumor target cells with increased efficiency as determined by FACS analysis. They also induce twice the amount of apoptosis of target tumor cells than the control antibodies. Furthermore, the modified antibodies inhibit tumor growth in culture more efficiently than the control antibodies. Criss-cross protocols in FACS, apoptosis, and growth inhibition indicate the specificity of targeting the BCR with autophilic antitumor antibodies. The chemical approach of increasing the binding of antibodies without creating chemically crosslinked dimers mimics naturally occurring autophilic antibodies and represents a simple and attractive alternative to chemical dimerizing and antibody engineering techniques for improving their antitumor effect. Furthermore, these results provide a guide to incorporate the self-binding peptide into the structure of antibodies using modeling and molecular crafting techniques. **Key Words:** Antibody—Apoptosis—B-cell lymphoma—Homodimer.

---

Antibodies, being a major arm of adaptive immunity, improve their targeting ability after antigen challenge through mechanisms of somatic mutation and receptor editing in concert with clonal selection. These mechanisms require the help of T-cells that recognize peptides derived from protein antigens. For nonprotein antigens, such as carbohydrates, these mechanisms are not available, because T cells typically do not recognize carbohydrate. Thus, antibodies against carbohydrate antigens are mostly of the IgM class with close resemblance to the

germline gene structure. The polymeric structure of IgM, providing the benefit of subunit mediated increase in avidity, compensates for the lack of T-cell dependent affinity maturation. The avidity bonus from covalent antibody polymerization can also be obtained through non-covalent intermolecular homophilic interactions via (i) the Fc-Fc mediated dimerization in mouse IgG3 class antibodies (1) and (ii) the Fab-Fab mediated self-binding of autophilic antibodies (2,3).

The self-binding property of antibodies was discovered in a group of mouse antibodies that form soluble self-complexes without chemical bonds (2). Subsequently, we described a peptide region in the variable domain of a self-binding antibody (autobody) that inhibits the self-aggregation (4). The peptide is derived from

---

Received March 13, 2002; accepted June 18, 2002.

Address correspondence and reprint request to Heinz Kohler, M.D., Ph.D., Combs Research Building Room 203, Markey Cancer Center, University of Kentucky, 800 Rose Street, Lexington, KY 40536-0096, U.S.A.; E-mail: hkohl00@pop.uky.edu.

the variable domain of the heavy chain and comprises regions of CDR2 and FR3 of the germline encoded S107/TEPC15 (T15) antibody. The autophilic site is present on antibodies with different specificity (5) rendering its expression independent of antigen driven selection. Because of the antigen-independent expression of the autophilic effect, we considered the possibility to attach the autophilic peptide to monomeric antibodies and to create polymeric antibodies with increased avidity. This hypothesis was tested by affinity crosslinking the autophilic T15 peptide to antibodies against the B-cell receptor (BCR) of lymphoma tumors.

The antitumor effect of antibodies against the BCR is mediated by negative signaling requiring crosslinking of the BCR (6–9). This signal for growth arrest and apoptosis (10,11) of the B-cell tumor is greatly enhanced by homodimerizing antibodies that occur either spontaneously (12) or can be manufactured by chemical crosslinking (13).

In a recent study (14), we have generated an autophilic antibody against CD-20 of human B-cell lines and shown enhanced antitumor effects. Here we extended this approach using antibodies against the BCR molecule of a human and a murine B-cell line and demonstrate a monomer-dimer equilibrium of autophilic antibodies in solution that are not chemically crosslinked.

## MATERIALS AND METHODS

### Cell Line and Antibodies

The human B-cell tumor line (Su-DHL4) and murine B-cell tumor line (38C13) are grown in RPMI 1640 medium (supplemented with 10% fetal bovine serum, 2  $\mu\text{mol/L}$  glutamine, 10  $\mu\text{mol/L}$  HEPES, 50 U/mL penicillin, and 50  $\mu\text{g/mL}$  streptomycin, 50  $\mu\text{mol/L}$  2-mercaptoethanol) at 37°C under 5%  $\text{CO}_2$ . Two mAb 5D10 and S1C5, specific for the human or murine BCR, respectively, were used in this study. The antibodies are purified from the culture supernatant by protein G and protein A affinity chromatography.

### Synthesis of Antibody-Peptide Conjugate

T15H peptide (ASRNKANDYTTDYSASVKGRFIVSR), a  $V_H$ -derived peptide from a self-binding antibody-T15 (5), was synthesized by Genemed Synthesis (San Francisco, CA, U.S.A.). Antibodies were dialyzed against PBS (pH 6.0) and 1/10 volume of 200  $\mu\text{mol/L}$   $\text{NaIO}_4$  was added and incubated at 4°C for 30 minutes in the dark. The reaction was stopped by adding glycerol to 30  $\mu\text{mol/L}$ , and the sample was dialyzed at 4°C for 30 min-

utes against PBS (pH 7.0). 100 times molecular excess of T15H or scrambled peptide was added to the antibodies and incubated at 37°C for 1 hour. L-Lysine was added and incubated at 37°C for 30 minutes to block the remained aldehyde group. The same oxidation reaction steps (except adding the peptides) were applied to antibodies used as controls. After the blocking step, the antibody-conjugates were dialyzed against PBS (pH 7.2) overnight.

### Ig Capture ELISA

Four  $\mu\text{g/mL}$  of S1C5-T15H was coated to Costar vinyl assay plates (Costar, Cambridge, MA, U.S.A.). After blocking with 3% BSA solution, 8  $\mu\text{g/mL}$  of photobiotinylated S1C5-T15H (15), S1C5-scrambled peptide conjugate, and control S1C5 were added to the first wells, and 1:1 dilution was performed. The antibodies were incubated for 2 hours at room temperature. After washing with PBS buffer, Avidin-HRP (Sigma, St. Louis, MO, U.S.A.) was added as a 1:2500 dilution. The binding antibodies were visualized by adding substrate *o*-phenylenediamine.

### Size Exclusion Chromatography

Antibody conjugate was chromatographed on a 75 mL Sephacryl 300HR column (Pharmacia, Peapack, NJ, U.S.A.). 1:10 diluted PBS (pH 7.2) was chosen as elution buffer. Fractions (0.5 mL/each) were collected and aliquots (100  $\mu\text{L}$ ) were assayed on antihuman IgG capture ELISA. The ELISA reading (OD 490 nm) is plotted against elution volume.

### Viability Assay for Antibody-Treated Cells

The lymphoma cells were grown in 96-well tissue culture wells in 1-mL medium. 2  $\mu\text{g}$  of antibodies or antibody-peptide conjugates were added and incubated for various times as described in the “RESULTS” section. Ten  $\mu\text{L}$  aliquots from the cell suspension were used to determine viability by using trypan blue exclusion.

### FACS Assay of the B-Cell Lymphoma

The Su-DHL4 and 38C13 cells were fixed with 1% paraformaldehyde.  $1 \times 10^6$  cells were suspended in 50  $\mu\text{L}$  of staining buffer (Hank's balanced salt solution, containing 0.1%  $\text{NaN}_3$ , 1.0% BSA), then 1.5  $\mu\text{g}$  of photobiotinylated S1C5-T15H conjugates (15) was added and incubated for 30 minutes on ice. Control antibodies and antibody-scrambled T15 peptide conjugates served

as controls. The cells were washed twice with staining buffer before Avidin-FITC (Sigma) was added to the cells for 30 minutes on ice. Then the cells were washed twice with staining buffer, resuspended in 200  $\mu$ L PBS and analyzed by flow cytometry.

#### **Hoechst-Merocyanin 540 Staining to Detect Apoptosis**

$1 \times 10^6$  of lymphoma cells were placed into 24-well tissue culture wells. Four  $\mu$ g of antibodies or antibody-peptide conjugates were added and incubated for various times as described in the "RESULTS" section.  $1 \times 10^6$  cells were removed from the culture, resuspended in 900  $\mu$ L cold PBS (pH 7.2). One hundred  $\mu$ L of Hoechst 33342 (50  $\mu$ g/mL; Molecular Probe, Eugene, OR, U.S.A.) was added, the cells were incubated at 37°C for 30 minutes in the dark. The cells were centrifuged and resuspended in 100  $\mu$ L PBS. Then, 4  $\mu$ L of MC540 solution (Molecular Probe) was added, and a 20-minute incubation was performed at room temperature in the dark. The cells were pelleted, resuspended in 1 mL cold PBS (pH 7.2), and analyzed by flow cytometry (16).

### **RESULTS**

#### **Characterization of Autophilic Antibodies**

The T15H (24-mer) peptide (4) was crosslinked to two murine mAb (S1C5 and 5D10), using carbohydrate periodate conjugation (17). The mAb S1C5 (IgG1) is specific for the tumor idiotype of the mouse 38C13 B-cell line (18) and the 5D10 antibody for the human Su-DHL4 B-cell tumor (19). Both antibodies recognize unique idiotypes of the BCR IgM on the B-cell tumors.

#### **Self-Binding Behavior can Easily be Demonstrated by ELISA**

The autophilic self-binding effect was studied with the T15H peptide-crosslinked mAb S1C5. As seen in Figure 1A (panel A), the T15H-crosslinked S1C5 binds to insolubilized S1C5-T15H detected by biotin-avidin ELISA. Control S1C5 does not bind significantly to S1C5-T15H or S1C5 crosslinked with a scrambled peptide. Similar self-binding of T15H peptide-crosslinked mAb 5D10 to insolubilized T15H-5D10 was also observed (Fig. 1A [panel B]).

The specificity of the peptide mediated autophilic effect was tested using the 24 mer peptide T15H itself as an inhibitor. As seen in Figure 1B, only the T15H peptide inhibited S1C5-T15H (Fig. 1B [panel A]) and 5D10-

T15H (Fig. 1B [panel B]) self-binding while the control scrambled peptide did not inhibit it. These results are similar to the previously published inhibition data with the naturally occurring autophilic T15/S107 antibody (4,5).


#### **T15H-Antibody Conjugates Form an Equilibrium of Monomer and Dimer in Solution**

The noncovalent nature of the self-aggregation of T15H-linked antibodies raises the question of its physical state in solution. To address this issue, we analyzed the molecular species of T15H-linked mAb using gel electrophoresis and sizing gel filtration. In Figure 1C, the electrophoretic mobility of control and T15H peptide-conjugated S1C5 and 5D10 under reducing and nonreducing conditions show no differences, indicating the absence of chemical bonds between the antibody chains. The faint band in lanes 3 and 4 of Figure 1C represent dimers of T15H-linked mAb.


The molecular species of the peptide conjugated antibodies (5D10-T15H) was further analyzed by size exclusion chromatography. In Figure 2, representative results are shown. The elution profile indicated two immunoglobulin species of different size (Fig. 2A). The second smaller peak eluted in the position of nonconjugated 5D10 antibody. The larger first peak eluted in the position of an antibody dimer. The appearance of two peaks resembled monomer and dimer antibodies and could indicate that either a fraction of antibodies was not modified to polymerize, or that the modification was complete and the antibody establishes an equilibrium of dimers and monomers. To test the latter possibility, material from both peaks were subjected to a second gel filtration on the same column. Reruns of both peaks yielded again two peaks (Figs. 2B and C) at the same position as in the first chromatography. The inserts in Figure 2 show the SDS-PAGE of the material from peak I and II, indicating the typical heavy (H) and light (L) chain bands of antibodies. These data show that the T15H peptide-linked antibodies exist in solution as two distinct molecular species that form an equilibrium of monomer and dimer. This behavior is reminiscent of the gel filtration data on the natural self-binding antibody T15 (20).

#### **Enhanced Binding of Autophilic Antibodies to Tumors**

The binding of the peptide conjugated antibodies against their respective tumor targets was compared with that of the control antibodies in indirect fluorescence activated cell sorting (FACS). As control, antibodies



**FIG. 1.** (A) Self-binding of autophilic S1C5 (panel A) and 5D10 (panel B). Four  $\mu\text{g/mL}$  of antibody-T15H was coated to Costar vinyl assay plates. After blocking with 3% BSA solution, 8  $\mu\text{g/mL}$  of photobiotinylated antibody-T15H, antibody-scrambled peptide conjugate, and control antibody were added to the first wells, and 1:1 dilution was performed. After a 2-hour incubation at room temperature, Avidin-HRP was added as a 1:2500 dilution. The binding antibodies were visualized by adding substrate *o*-phenylenediamine. (B) Inhibition of self-binding. Four  $\mu\text{g/mL}$  of photobiotinylated antibody-T15H was mixed with different concentrations of T15H or scrambled peptide and added to antibody-T15H coated plates (400 ng/well), incubated for 2 hours at room temperature, and the binding was developed as described in (A). (C) SDS-PAGE of autophilic antibodies. PAGE in reducing and nonreducing conditions of nonmodified and peptide-conjugated mAb S1C5 and 5D10. Lanes 1 and 3 show the control antibodies, lanes 2 and 4 are the peptide-conjugated antibodies; Std, molecular weight standard.




**FIG. 2.** Size exclusion chromatography of 5D10-T15H. Antibody conjugates were chromatographed on a 75-mL Sephacryl 300HR column. 1:10 diluted PBS (pH 7.2) was chosen as elution buffer. Fractions (0.5 mL/each) were collected and aliquots (100  $\mu$ L) were assayed on antihuman IgG capture ELISA. The ELISA reading (OD 490nm) is plotted against elution volume. The elution of IgM, dimer IgA, and monomer IgG are indicated in (A). Inserts show the SDS-PAGE of the materials from the peak fractions I and II; H and L indicate the heavy and light chain bands. (A) Elution profile of 5D10-T15H. (B) Elution profile of peak I. (C) Elution profile of peak II.

linked with a scrambled peptide were included. In Figure 3A, the fluorescence intensity of the T15H-S1C5 on 38C13 cells (Fig. 3A [panel D]) is compared with that by the control S1C5 (Fig. 3A [panel B]) and the scrambled peptide S1C5 (Fig. 3A [panel C]). The difference in mean fluorescence channels between S1C5-T15H and controls was greater than 1 log. Similarly, the FACS analysis of autophilic 5D10-T15H on Su-DHL4 cells shows enhancement of binding over binding of control 5D10 and control peptide-crosslinked 5D10 (Fig. 3A [panel D versus panels B and C]). In both tumor systems, the conjugation of the T15H peptide to tumor-specific antibody enhanced the FACS signals over control antibodies used at the same concentration. The enhancement of fluorescence can be explained with the increase of targeting antibodies caused by self-aggregation and lattice formation on the surface of the tumor cells.

### Inhibition of Tumor Growth

Antibodies binding to the BCR induce crosslinking of the BCR, which, in turn, inhibits cell proliferation (21) and produces a death signal (22,23). Furthermore, chemically dimerized antibodies directed against a B-cell tumor induce hyper-crosslinking of the BCR followed by inhibition of cell division and apoptosis of the tumor (12,13). To see if similar enhancement of the antitumor effects of dimerizing antibody were induced by our non-covalent dimerizing T15H-linked antibodies, the two B-cell tumors were cultured in the absence or presence of control and T15H-linked antibodies. As shown in a representative experiment (Fig. 4A), co-culture of both tumors, 38C13 (Fig. 4A [panel A]) and Su-DHL4 (Fig. 4A [panel B]) with their respective T15H-linked antibodies inhibited the cell growth significantly better compared with the control antibodies.

To test the tumor target specificity of autophilic antibodies in growth inhibition, criss-cross experiments were performed with the 38C13 and Su-DHL-4 cell lines. Inhibition of 38C13 cell growth with S1C5-T15H was statistically greater than mismatched 5D10-T15H (Fig. 4B



**FIG. 3.** FACS analysis of tumor cells after incubation with modified antibodies.  $1 \times 10^6$  cells were suspended in 50  $\mu$ L of staining buffer, then 1.5  $\mu$ g of photobiotinylated S1C5-T15H conjugates was added and incubated for 30 minutes on ice. Control antibodies and antibody-scrambled T15 peptide conjugates served as controls. After washing step, avidin-FITC was added to the cells for 30 minutes on ice. After washing, the cells were resuspended in 200  $\mu$ L PBS and analyzed by flow cytometry. **(A)** 38C13 cells. (Panel A) No primary antibody; (panel B) stained with S1C5; (panel C) Stained with S1C5-scrambled peptide conjugate; (panel D) stained with S1C5-T15H peptide conjugate. **(B)** The Su-DHL4 cells. (Panel A) No primary antibody; (panel B) stained with 5D10; (panel C) stained with 5D10-scrambled peptide conjugate; (panel D) stained with 5D10-T15H conjugate.

[panel A]). Similar results on the specificity of autophilic antibodies were obtained with the Su-DHL4 cells (Fig. 4B [panel B]).

### Induction of Apoptosis

As suggested by earlier studies (21–23), the antitumor effect of antibodies directed against the BCR of B-cell lymphomas in vitro and in vivo might be caused by the induction of apoptosis. Aliquots of tumor cells (38C13 and Su-DHL4) cultured in the presence of control or T15H-linked antibodies were analyzed for apoptosis using a double stain FACS protocol (16). The results are summarized in Table 1. 38C13 and Su-DHL4 cells underwent a moderate amount of apoptosis without antibodies over a 6, respectively 18-hour culture. This apoptosis was enhanced when the respective antibody was added. However, when the T15H-linked antibodies were added, the accumulated number of apoptotic 38C13 cells

was almost doubled, and apoptosis of Su-DHL4 cells was more than doubled during the entire culture.

### DISCUSSION

The biologic advantage of the autophilic property is exemplified with the S107/T15 antiphosphorylcholine antibody (2). This self-binding antibody is several times more potent in protecting immune-deficient mice against infection with pneumococci pneumoniae (24,25) than nonself-binding antibodies with the same antigen specificity and affinity.

As shown here, the autophilic antibody function can be transferred to other antibodies by chemically crosslinking a peptide derived from the T15 V<sub>H</sub> germline sequence. The modified antibody mimics the self-binding property of the T15/S107 antibody (2), producing a dimeric antibody with increased avidity and enhanced targeting. This approach is an attractive alternative to strategies of improving the targeting of antibodies by either chemical crosslinking or by antibody engineering.

Enhancing the binding of autophilic engineered antibodies to the BCR of B-cell tumor increases the strength of the death signals leading to profound inhibition of cell proliferation in culture. Even though the doubling of apoptosis is demonstrated here, it appears that other mechanisms of growth inhibition are involved.

Crosslinking the BCR of the mature murine B-cell lymphoma A20 can protect against CD95 mediated apoptosis (26). This antiapoptotic activity of engagement of the BCR by crosslinking antibodies is highly restricted to the time window of CD95 stimulation and is not dependent upon protein synthesis (27). Our finding that BCR hypercrosslinking per se is pro-apoptotic is not at variance with reports on the antiapoptotic activity of the BCR engagement, because it can be a result of the use of less mature B-cell lines in our study, to different strength of delivered signals by homodimerizing antibodies, or to Fas independent apoptosis (23,28,29).

The use of two BCR idiotope specific antibodies against different tumors offered the opportunity to test the biologic effect of targeting receptors other than the idiotope specific BCR. In criss-cross experiments with autophilic antibodies binding in FACS analysis and inhibition of growth in vitro show a significant enhancement only with the autophilic matched antibody. In this context, it is interesting to speculate whether enhanced tumor targeting would also augment cellular effector functions. Such in vitro and in vivo experiments are in progress.


In an earlier study (13) using chemically homodimer-

**TABLE 1.** Analysis of apoptotic cells

Tumor cells*	38C13		Su-DHL4	
Culture time (hours)	3	6	9	18
Antibodies	None		None	
R1: G <sub>0</sub> /G <sub>1</sub> viable	58.24†	61.21	57.75	44.29
R2: S/G <sub>2</sub> /M viable	34.05	30.07	33.68	49.38
R3: G <sub>0</sub> /G <sub>1</sub> apoptotic	2.97	3.40	3.91	1.16
R4: S/G <sub>2</sub> /M apoptotic	2.63	3.31	3.52	1.55
R5: Fragmented	0.57	0.97	0.08	0.24
Σ(R3,R4,R5): apoptotic	6.17	7.68	7.51	2.95
Antibody	S1C5		5D10	
R1: G <sub>0</sub> /G <sub>1</sub> viable	61.87	57.29	57.14	44.41
R2: S/G <sub>2</sub> /M viable	27.68	27.29	31.84	43.58
R3: G <sub>0</sub> /G <sub>1</sub> apoptotic	3.99	4.59	5.40	1.93
R4: S/G <sub>2</sub> /M apoptotic	2.80	4.71	4.83	1.87
R5: Fragmented	2.91	5.56	0.18	1.43
Σ(R3,R4,R5): apoptotic	9.7	14.86	10.41	5.23
Antibody-T15H	T15-S1C5		T15-5D10	
R1: G <sub>0</sub> /G <sub>1</sub> viable	49.72	45.18	48.98	44.68
R2: S/G <sub>2</sub> /M viable	30.21	23.02	30.55	26.17
R3: G <sub>0</sub> /G <sub>1</sub> apoptotic	7.42	7.18	7.75	10.90
R4: S/G <sub>2</sub> /M apoptotic	7.45	10.47	6.82	9.01
R5: Fragmented	5.80	6.85	1.88	1.76
Σ(R3,R4,R5): apoptotic	20.67	24.5	16.45	21.67

\* 38C13 and Su-DHL4 cells were cultured in absence and presence of 2 µg of antibody or antibody peptide conjugate. After a certain time (3 and 6 hours for 38C13; 9 and 18 hours for SU-DHL4) of incubation, the cells were stained with Hoechst 342 and MC540 and analyzed by flow cytometry as described (15).

† Percent of analyzed cells (10,000): R1, cells with 2n DNA that are MC 540 negative; R2, cells with greater than 2n DNA that are MC 540 negative; R3, cells with 2n DNA that are MC 540 bright; R4, cells with greater than 2n DNA that are MC 540 bright; R5, cells displayed reduced Hoechst 342 staining and MC 540 bright.



**FIG. 4.** Inhibition of tumor growth. (A) 38C13 ( $1 \times 10^5/\text{mL}$ ) (panel A) and SU-DHL4 cells ( $5 \times 10^5/\text{mL}$ ) (panel B) were cultured in 1 mL tissue culture wells; 2  $\mu\text{g}$  of antibodies or (autophilic) T15H-antibody were added. After 3 and 6 hours (for 38C13) and 9 and 18 hours (for Su-DHL4) of incubation, the cell viability was determined by trypan blue exclusion. The number of viable cells is plotted at different hours of culture. (B) Criss-cross tumor growth inhibition. 38C13 ( $1 \times 10^5/\text{mL}$ ) (panel A) and SU-DHL4 cells ( $5 \times 10^5/\text{mL}$ ) (panel B) were cultured in presence of S1C5-T15H and 5D10-T15H antibodies as in (A). \*No statistically significant differences between the unmatched antibody and no antibody control,  $p \geq 0.1$ .

ized antibodies, the Fc domain was not involved in the augmentation of growth inhibition and tumor cells lacking Fc receptors were susceptible to the antigrowth activity of homodimers. Thus, the antitumor effect induced by dimerizing antibodies would not be restricted to tumors expressing Fc-receptors (30,31).

The described approach of transferring the naturally occurring autophilic property to other antibodies thereby enhancing their antitumor effect outlines a general method to improve the therapeutic efficacy of antibodies in passive immunotherapy. Such noncovalent antibody

complexes offer several advantages over chemically crosslinked antibodies: (i) the equilibrium between monomer and noncovalent homopolymers prevents the formation of precipitating nonphysiologic complexes in solution (this report and [20]); (ii) autophilic conversion does not compromise the structural integrity of antibodies; and (iii) the method is simple and efficient and does not require a purification step typically needed for chemically crosslinked homodimers that reduces the yield of active Ig dimers. One possible limitation of the approach of using dimerizing antibodies might be the



ability to penetrate a large tumor mass. Because the homophilic peptide is of murine origin, it might be immunogenic in humans. Thus, it could be necessary to humanize the murine peptide based on sequence and structural homology using computer modeling. The demonstration that adding a single peptide to the structure of antibodies increases the amount of antibody bound to targets and the antitumor activity encourages attempts to engineer recombinant antibodies expressing the autophilic activity.

**Acknowledgments:** This work was supported in part by a grant from the Tobacco Research Council. We would like to thank Dr. Charlie Snow at the University of Kentucky and Dr. Srinivasa Kaveri at INSERM, Hopital Broussais (Paris, France) for helpful discussion and Ronald Levy at Stanford University for providing the B-cell tumor lines and the antiidiotypic antibodies. The help of D. Luo has also been appreciated.

## REFERENCES

1. Gytoku Y, Abdelmoula M, Sperini F, et al. Cryoglobulinemia induced by monoclonal immunoglobulin G rheumatoid factors derived from autoimmune MRL/MpJ-lpr/lpr mice. *J Immunol* 1987; 138:3785–92.
2. Kang CY, Kohler H. Immunoglobulin with complementary paratope and idiotope. *J Exp Med* 1986;163:787–92.
3. Yan X, Evans SV, Kaminski MJ, et al. Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. *J Immunol* 1996;157:1582–8.
4. Kang CY, Brunck TK, Kieber-Emmons T, et al. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. *Science* 1988;240:1034–6.
5. Kaveri S, Halpern R, Kang CY, et al. Antibodies of different specificities are self-binding: implication for antibody diversity. *Mol Immunol* 1991;2:733–78.
6. Scott DW, Tuttle J, Livnat D, et al. Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti- $\mu$  of WEHI-231 and the selection and properties of resistant mutants. *Cell Immunol* 1985;93:124–31.
7. Bridges SH, Kruisbeek AM, Longo DL. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma. *J Immunol* 1987;139:4242–9.
8. Ghetie MA, Tucker K, Richardson JA, et al. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. *Blood* 1992;80:2315–20.
9. Vitetta ES, Uhr JW. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. *Cancer Res* 1994;54: 5201–5309.
10. Hamblin TJ, Abdul-Ahab AK, Gordon J, et al. Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. *Br J Cancer* 1980;42: 495–502.
11. Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. *J Natl Cancer Inst Monogr* 1990;10:61–8.
12. Ghetie MA, Picker LJ, Richardson JA, et al. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. *Blood* 1994;83: 1329–36.
13. Ghetie MA, Podar EM, Ilgen A, et al. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. *Proc Natl Acad Sci USA* 1997;94:7509–14.
14. Zhao Y, Lou D, Burke J, et al. Enhanced anti B-Cell tumor effects with anti-CD20 superantibody. *J Immunotherapy*, 2002;25:57–62.
15. Pavlinkova G, Rajagopalan K, Muller S, Chavan A, Sievert G, Lou D, O'Toole C, Haley B, and Kohler H. Site-specific photobiotinylation of immunoglobulins, fragments and light chain dimers. *J Immunol. Methods* 1997;201:77–88.
16. Reid S, Cross R, and Snow EC. Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage, viability and apoptosis. *J. Immunol. Methods* 1996;192:43–54.
17. Awad M, Strome PG, Gilman SC, and Axelrod HR. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions. *Cancer. Immunol. Immunother.* 1994;38:23–30.
18. Maloney DG, Kaminski MS, Burowski D, Haimovich J, and Levy R. Monoclonal anti-idiotypic antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. *Hybridoma* 1985;4:191–209.
19. Campbell MJ, Esserman L, Byars NE, Allison AC, and Levy R. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. *Intern. Rev. Immunol* 1989;4:251–270.
20. Kaveri SV, Halpern R, Kang CY, and Kohler H. Self-binding antibodies (autobodies) from specific complexes in solution. *J. Immunol.* 1990;145:2533–2538.
21. Ward RE, McNamara-Ward M, Webb CF, Altman D, Lim PK, Tucker PW, and Kohler H. Regulation of an idiotype+ B cell lymphoma. Effects of antigen and anti-idiotypic antibodies on proliferation and Ig secretion. *J. Immunol.* 1988;141:340–345.
22. Hasbold J, and Klaus GGB. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. *Eur. J. Immunol.* 1990;20:1685–1690.
23. Wallen-Ohman M, Lonnbro P, Schon A, and Borrebaeck CAK. Antibody-induced apoptosis in a human leukemia cell line is energy dependent: thermochemical analysis of cellular metabolism. *Cancer Lett* 1993;75:103–109.
24. Briles DE, Forman C, Hudak S, and Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against *Streptococcus pneumoniae*. *J. Exp. Med.* 1982;156:1177–1185.
25. Lim PL, Choy WF, Chan ST, Leung DT, and Ng SS. Transgene-encoded antiphosphorylcholine (T15+) antibodies protect CBA/N (xid) mice against infection with *Streptococcus pneumoniae* but not *Trichinella spiralis*. *Infect Immun.* 1994;62:1658–1661.
26. Bras A, Martinez-A C, and Baixeras E. B cell receptor cross-linking prevents Fas-induced cell death by inactivating the IL-1 beta-converting enzyme protease and regulating Bcl-2/Bcl-x expression. *J Immunol.* 1997;159:3168–3177.
27. Catlett IM, and Bishop GA. Cutting edge: a novel mechanism for rescue of B cells from CD95/Fas-mediated apoptosis. *J. Immunol.* 1999;163:2378–2381.
28. Berndt C, Mopps B, Angermuller S, Gierschik P, and Krammer P. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. *Proc. Natl. Acad. Sci. USA* 1998;95:12556–12561.
29. Lens SMA, den Drijver BFA, Potgens AJ, Tesselaar K, van Oers MHJ, and Van Lier RAW. Dissection of pathways leading to antigen receptor-induced and Fas/CD95-induced apoptosis in human B cells. *J. Immunol.* 1998;160:6083–6092.
30. Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC. Synergistic antitumor activity with IFN and monoclonal anti-idiotypic for murine B cell lymphoma. Mechanism of action. *J. Immunol.* 1988;141:2855–2860.
31. Rozsnyay Z., Sarma G., Szabo I., Medgyesi G., Gorini G. and Gergely J. Fine specificity of rabbit antibody interacting with human IgG Fc receptor-like molecules. *Immunol Lett.* 1990. 25:3403–311.